Should we debulk the primary tumor in some men with metastatic prostate cancer?

Back in the 1980s, it would never (well, probably nearly never) have crossed anyone’s mind to carry out any type of primary tumor-debulking treatment on any patient who was newly diagnosed with evident, metastatic prostate cancer. … READ MORE …

Focal therapy today: upsides and downsides

While there is considerable allure to the theory behind focal therapy (and focal laser therapy or FLA in particular) as a treatment for some men with localized prostate cancer, it is worth understanding that there are good reasons to consider this allure with great caution. … READ MORE …

Factors in the sequencing of late-stage prostate cancer treatments

A paper in the International Journal of Cancer offers information on the sequencing of cabazitaxel (CAB) and abiraterone acetate (ABI) in men with metastatic, castration-resistant prostate cancer (mCRPC) who have already progressed after treatment with docetaxel. … READ MORE …

First 6 months of first off-therapy cycle may determine effectiveness of intermittent ADT

A new paper in Clinical Genitourinary Cancer provides some intriguing information about determining the likelihood of good and less good long-term responses to intermittent androgen deprivation therapy (ADT) among men with non-metastatic prostate cancer. Be warned: This is going to be a long post with a lot of data. … READ MORE …

Poorer outcomes for BRCA1/2 carriers after standard treatment

It is not entirely surprising to come across a paper suggesting that male carriers of the BRCA1/2 genes are at risk for worse post-treatment outcomes than non-carriers of these genes after standard forms of first-line treatment for prostate cancer. … READ MORE …

7-year outcomes data after treatment with SBRT

A new article in Frontiers in Oncology now provides us with data from the median 6-year follow-up of > 450 men with prostate cancer treated with stereotactic body radiation therapy (SBRT) using the CyberKnife technology. … READ MORE …

15-year survival and related data after first-line brachytherapy

Stone, Stock, and colleagues at the Icahn School of Medicine at Mount Sinai, New York, have been treating prostate cancer patients with brachytherapy since 1990 and (to whatever extent was possible) maintaining meticulous records throughout that time period. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,169 other followers